Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company based in San Carlos, California, that develops and commercializes novel cancer immunotherapies. The company specializes in tumor-infiltrating lymphocyte (TIL) therapies, a personalized treatment that harnesses a patient's own immune cells to target and destroy solid tumors. Its flagship product, Amtagvi (lifileucel), is the first FDA-approved individualized T-cell therapy for advanced melanoma. The company's proprietary TIL platform involves extracting immune cells from a patient's tumor, expanding them ex vivo, and reinfusing them to attack the cancer. In addition to melanoma, Iovance is advancing a clinical pipeline of TIL therapies for other solid tumors, including non-small cell lung cancer and cervical cancer. To support its commercial and clinical operations, the company also owns the worldwide rights to Proleukin (interleukin-2), a biologic product administered alongside its TIL treatments to enhance their efficacy.
